The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results
Kokoreva, L.N.; Zmyzgova, A.V.; Shalygina, N.B.
Terapevticheskii Arkhiv 68(2): 10-14
1996
ISSN/ISBN: 0040-3660 PMID: 8771646 Document Number: 468346
The paper presents clinicoimmunological characterization or therapeutic efficacy of alpha-interferons produced in Russia and criteria of their administration in patients with chronic viral hepatitis. A 6 to 12 months course (single dose 1 x 10(6)-3 x 10(6) IU improves the disease running, hepatic function and corrects immune status in 55.6% of patients with chronic active hepatitis eventuating in liver cirrhosis and in 57.9% of patients in chronic active hepatitis of moderate activity. Alpha-interferons are indicated in chronic active hepatitis and cirrhosis under high activity of cytolytic process, immunodeficiency, weak autoimmune process and protein shifts.
Document emailed within 1 workday
